Global Restructuring And US Biologics Bet Could Be A Game Changer For GSK (LSE:GSK)

What happened: GSK is cutting jobs in Belgium and closing a German vaccine site under a US$2.50 billion global restructuring, while committing over US$800.00 million to expand its Pennsylvania biomanufacturing campus. Key numbers: US$2.50 billion restructuring; US$800.00 million US expansion; narrative projects £37.2 billion revenue and £7.0 billion earnings by 2029; £21.73 fair value cited. Why it matters: The article says these moves do not materially change near term focus on upcoming data and regulatory decisions, while HIV loss of exclusivity and R&D execution remain key risks.

GSK is cutting jobs in Belgium and closing a German vaccine site under a US$2.50 billion global restructuring, while committing over US$800.00 million to expand its Pennsylvania biomanufacturing campus.

The article says these moves do not materially change near term focus on upcoming data and regulatory decisions, while HIV loss of exclusivity and R&D execution remain key risks.